ChREBP drives diabetic kidney disease, and its inhibition confers renal protection
Chronic kidney disease (CKD) represents a major medical burden. Diabetic kidney disease (DKD) is a leading cause of CKD, but intracellular pathways that can be pharmacologically targeted are poorly defined. Using transcriptome screening of DKD model mice we found that a carbohydrate-responsive element-binding protein (ChREBP)-dependent transcriptional cascade is markedly up-regulated in diabetic kidneys. Genetic ablation of ChREBP in diabetic mice ameliorated DKD, establishing ChREBP as a potential causal driver. A chemical screen based on ChREBP transcriptional activity identified D-532 as a small-molecule inhibitor that is effective in human and rodent cells. Oral administration of D-532 protected multiple diabetic mouse models from DKD progression and suppressed ChREBP and its downstream targets, including genes associated with excessive reactive oxygen species production. These findings position ChREBP as a pharmacologically targetable transcriptional driver of DKD and provide proof of concept that ChREBP inhibition can confer renal protection.
Authors
- Yotaro Matsumoto (ORCID: https://orcid.org/0000-0001-8498-1341)
- Susumu Suzuki (ORCID: https://orcid.org/0000-0002-1466-8824)
- Shigeaki Kato (ORCID: https://orcid.org/0000-0002-5564-1695)
- Atsushi Yokoyama (ORCID: https://orcid.org/0000-0003-2842-4334)
- Koji Okamoto (ORCID: https://orcid.org/0000-0001-7587-0164)
- Genki Kudo
- Hiroyuki Yamakoshi (ORCID: https://orcid.org/0000-0002-9263-577X)
- Ryo Ito (ORCID: https://orcid.org/0009-0008-0791-4127)
- Kosuke Ohsawa (ORCID: https://orcid.org/0000-0002-7895-1573)
- Takatsugu Hirokawa (ORCID: https://orcid.org/0000-0002-3180-5050)
- Tatsuya Takemoto (ORCID: https://orcid.org/0000-0003-1860-0269)
- Shun Sawatsubashi (ORCID: https://orcid.org/0000-0003-3093-8334)
- Akira Sugawara (ORCID: https://orcid.org/0000-0003-4511-8101)
- Yoshiharu Iwabuchi (ORCID: https://orcid.org/0000-0002-0679-939X)
- Yusuke Sasano (ORCID: https://orcid.org/0000-0002-3852-8607)
- Takumi Kouketsu (ORCID: https://orcid.org/0000-0003-1014-6532)
- Yuta Yoshizaki (ORCID: https://orcid.org/0000-0003-0047-2131)
- Takayuki Doi (ORCID: https://orcid.org/0000-0002-8306-6819)
- Kotone Teshima (ORCID: https://orcid.org/0009-0003-6820-7710)
- Thanh Phuong Nguyen (ORCID: https://orcid.org/0009-0005-9924-8261)
- Tomohiro Konno
- Mayu Kuroda (ORCID: https://orcid.org/0009-0007-0028-8920)
- Masaya Takahashi (ORCID: https://orcid.org/0009-0009-1339-3951)
- Hiroto Mizuno
- Sora Fujita (ORCID: https://orcid.org/0009-0007-9062-4886)
Institutions
- Fukushima Medical University (JP)
- University of Tsukuba (JP)
- Okayama University (JP)
- Tohoku University (JP)
- Juntendo University (JP)
- Transborder Medical Research Center (JP)
- Institute of Advanced Medical Sciences, Tokushima University (JP)
- Tokushima University (JP)
Publication Details
- Journal
- Proceedings of the National Academy of Sciences
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1073/pnas.2537870123
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Suzuken Memorial Foundation
- Japan Agency for Medical Research and Development
- Takeda Medical Research Foundation
- Manpei Suzuki Diabetes Foundation
- Japan Society for the Promotion of Science
- Institute for Enzyme Research, University of Tokushima